Literature DB >> 19736356

Association of time since deployment, combat intensity, and posttraumatic stress symptoms with neuropsychological outcomes following Iraq war deployment.

Brian P Marx1, Kevin Brailey, Susan P Proctor, Helen Z Macdonald, Anna C Graefe, Paul Amoroso, Timothy Heeren, Jennifer J Vasterling.   

Abstract

CONTEXT: Previous research has demonstrated neuropsychological changes following Iraq deployment. It is unknown whether these changes endure without subsequent war-zone exposure or chronic stress symptoms.
OBJECTIVE: To determine the associations of time since deployment, combat intensity, and posttraumatic stress disorder (PTSD) and depression symptoms with longer-term neuropsychological outcomes in war-deployed soldiers.
DESIGN: Prospective cohort study involving (1) soldiers assessed at baseline (median, 42 days prior to deployment) and following return from Iraq (median, 404 days after return and 885 days since baseline), and (2) soldiers more recently returned from deployment assessed at baseline (median, 378 days prior to deployment) and following return from Iraq (median, 122 days after return and 854 days since baseline assessment).
SETTING: Active-duty military installations. PARTICIPANTS: Two hundred sixty-eight male and female regular active-duty soldiers (164 with 1-year follow-up; 104 recently returned). MAIN OUTCOME MEASURES: Neuropsychological performances (verbal learning, visual memory, attention, and reaction time).
RESULTS: There was a significant interaction between time and PTSD symptom severity (B= -0.01 [unstandardized], P = .04). Greater PTSD symptoms were associated with poorer attention in soldiers tested at 1-year follow-up (B = 0.01, P = .03) but not in recently returned soldiers. At 1-year follow-up, mean adjusted attention error scores increased by 0.10 points for every 10 points on the PTSD scale. Greater combat intensity was associated with more efficient postdeployment reaction-time performances, regardless of time since deployment (B = 0.48, P = .004), with mean adjusted reaction efficiency scores increasing by 4.8 points for every 10 points on the combat experiences scale. Neither depression nor contextual variables (alcohol use and deployment head injury) were significantly related to neuropsychological outcomes.
CONCLUSIONS: In this study of army soldiers deployed to the Iraq war, only PTSD symptoms (among soldiers back from deployment for 1 year) were associated with a neuropsychological deficit (reduced attention). Greater combat intensity was associated with enhanced reaction time, irrespective of time since return.

Entities:  

Mesh:

Year:  2009        PMID: 19736356     DOI: 10.1001/archgenpsychiatry.2009.109

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  28 in total

1.  Project VALOR: design and methods of a longitudinal registry of post-traumatic stress disorder (PTSD) in combat-exposed veterans in the Afghanistan and Iraqi military theaters of operations.

Authors:  Raymond C Rosen; Brian P Marx; Nancy N Maserejian; Darren W Holowka; Margaret A Gates; Lynn A Sleeper; Jennifer J Vasterling; Han K Kang; Terence M Keane
Journal:  Int J Methods Psychiatr Res       Date:  2011-11-16       Impact factor: 4.035

Review 2.  Neuropsychological sequelae of PTSD and TBI following war deployment among OEF/OIF veterans.

Authors:  Sara Dolan; Sarah Martindale; Jennifer Robinson; Nathan A Kimbrel; Eric C Meyer; Marc I Kruse; Sandra B Morissette; Keith A Young; Suzy Bird Gulliver
Journal:  Neuropsychol Rev       Date:  2012-02-18       Impact factor: 7.444

Review 3.  Concurrent Treatment of Substance Use and PTSD.

Authors:  Julianne C Flanagan; Kristina J Korte; Therese K Killeen; Sudie E Back
Journal:  Curr Psychiatry Rep       Date:  2016-08       Impact factor: 5.285

4.  Posttraumatic stress disorder symptoms and cognitive function in a large cohort of middle-aged women.

Authors:  Jennifer A Sumner; Kaitlin Hagan; Fran Grodstein; Andrea L Roberts; Brian Harel; Karestan C Koenen
Journal:  Depress Anxiety       Date:  2017-01-10       Impact factor: 6.505

5.  Persistent and reversible consequences of combat stress on the mesofrontal circuit and cognition.

Authors:  Guido A van Wingen; Elbert Geuze; Matthan W A Caan; Tamás Kozicz; Silvia D Olabarriaga; Damiaan Denys; Eric Vermetten; Guillén Fernández
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

6.  Computerized neuropsychological assessment devices: joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology.

Authors:  Russell M Bauer; Grant L Iverson; Alison N Cernich; Laurence M Binder; Ronald M Ruff; Richard I Naugle
Journal:  Arch Clin Neuropsychol       Date:  2012-03-01       Impact factor: 2.813

7.  Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial.

Authors:  Julianne C Flanagan; Lauren M Sippel; Amy Wahlquist; Megan M Moran-Santa Maria; Sudie E Back
Journal:  J Psychiatr Res       Date:  2017-12-26       Impact factor: 4.791

8.  Computerized neuropsychological assessment devices: joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology.

Authors:  Russell M Bauer; Grant L Iverson; Alison N Cernich; Laurence M Binder; Ronald M Ruff; Richard I Naugle
Journal:  Clin Neuropsychol       Date:  2012-03-07       Impact factor: 3.535

9.  Alcohol misuse and psychological resilience among U.S. Iraq and Afghanistan era veterans.

Authors:  Kimberly T Green; Jean C Beckham; Nagy Youssef; Eric B Elbogen
Journal:  Addict Behav       Date:  2013-08-31       Impact factor: 3.913

10.  Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans.

Authors:  Sudie E Back; Julianne C Flanagan; Jennifer L Jones; Isabel Augur; Alan L Peterson; Stacey Young-McCaughan; David W Shirley; Aisling Henschel; Jane E Joseph; Brett T Litz; Allison K Hancock; John D Roache; Jim Mintz; Jennifer S Wachen; Terence M Keane; Kathleen T Brady
Journal:  Contemp Clin Trials       Date:  2018-08-24       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.